ValuEngine upgraded shares of Aldeyra Therapeutics (NASDAQ:ALDX) from a buy rating to a strong-buy rating in a research report released on Thursday.

Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald set a $30.00 target price on shares of Aldeyra Therapeutics and gave the stock a buy rating in a report on Thursday, February 28th. BidaskClub upgraded shares of Aldeyra Therapeutics from a sell rating to a hold rating in a report on Thursday, January 10th. Zacks Investment Research upgraded shares of Aldeyra Therapeutics from a sell rating to a hold rating in a report on Tuesday, December 25th. Finally, Citigroup began coverage on shares of Aldeyra Therapeutics in a report on Tuesday, December 4th. They issued a buy rating and a $23.00 target price for the company. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. Aldeyra Therapeutics currently has a consensus rating of Buy and a consensus target price of $30.40.

ALDX stock opened at $8.72 on Thursday. The firm has a market cap of $246.66 million, a price-to-earnings ratio of -4.87 and a beta of 0.77. Aldeyra Therapeutics has a 52 week low of $6.75 and a 52 week high of $16.70.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Friday, March 8th. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.04. On average, equities research analysts forecast that Aldeyra Therapeutics will post -1.7 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. FMR LLC lifted its holdings in Aldeyra Therapeutics by 59.1% during the 3rd quarter. FMR LLC now owns 2,564,333 shares of the biotechnology company’s stock valued at $35,388,000 after buying an additional 953,022 shares in the last quarter. 683 Capital Management LLC lifted its holdings in Aldeyra Therapeutics by 3.2% during the 4th quarter. 683 Capital Management LLC now owns 1,393,700 shares of the biotechnology company’s stock valued at $11,568,000 after buying an additional 43,700 shares in the last quarter. BlackRock Inc. lifted its holdings in Aldeyra Therapeutics by 63.0% during the 4th quarter. BlackRock Inc. now owns 1,298,715 shares of the biotechnology company’s stock valued at $10,779,000 after buying an additional 501,927 shares in the last quarter. Sphera Funds Management LTD. lifted its holdings in Aldeyra Therapeutics by 7.9% during the 4th quarter. Sphera Funds Management LTD. now owns 1,232,089 shares of the biotechnology company’s stock valued at $10,226,000 after buying an additional 90,000 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Aldeyra Therapeutics by 25.7% during the 3rd quarter. Vanguard Group Inc. now owns 947,876 shares of the biotechnology company’s stock valued at $13,081,000 after buying an additional 193,707 shares in the last quarter. Institutional investors own 66.11% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Recommended Story: What is Net Asset Value (NAV)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.